4-甲氧基苯氧基乙腈 | 22446-12-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 4-甲氧基苯氧基乙腈
• 中文别名: 4-甲氧基苯氧乙腈
• 英文名称: 2-(4-methoxyphenoxy)acetonitrile
• 英文别名: (4-methoxyphenoxy)acetonitrile；4-Methoxyphenoxyacetonitrile
• CAS: 22446-12-4
• 化学式: C₉H₉NO₂
• mdl: MFCD00017528
• 分子量: 163.176
• InChiKey: SNADCCRKYFVIEJ-UHFFFAOYSA-N

物化性质

• 沸点：
  106-110°C 0,1mm
• 密度：
  1.107
• 闪点：
  106-110°C/0.1mm
• 稳定性/保质期：

  如果按照规格使用和储存，则不会分解。请避免接触氧化物。

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  42.2
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险等级：
  6.1
• 危险品标志：
  Xn
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R20/21/22
• 海关编码：
  2926909090
• 包装等级：
  III
• 危险类别：
  6.1
• 危险品运输编号：
  3276
• 储存条件：
  保持贮藏器密封，并将其放入一个紧密的容器中。存放在阴凉、干燥的地方。

SDS

Name:	2-(4-Methoxyphenoxy)acetonitrile 97% Material Safety Data Sheet
Synonym:
CAS:	22446-12-4

Section 1 - Chemical Product MSDS Name:2-(4-Methoxyphenoxy)acetonitrile 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
22446-12-4	2-(4-Methoxyphenoxy)acetonitrile	97%	unlisted

Hazard Symbols: XN
Risk Phrases: 20/21/22 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful by inhalation, in contact with skin and if swallowed.
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. Harmful if absorbed through the skin.
Ingestion:
Harmful if swallowed. May cause irritation of the digestive tract.
Inhalation:
Harmful if inhaled. Causes respiratory tract irritation.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 22446-12-4: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Liquid
Color: colorless
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: 101 deg C @0.01mmHg
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C9H9NO2
Molecular Weight: 163

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Oxidizing agents, reducing agents, acids, bases.
Hazardous Decomposition Products:
Hydrogen cyanide, nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 22446-12-4 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
2-(4-Methoxyphenoxy)acetonitrile - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: NITRILES, LIQUID, TOXIC, N.O.S.*
Hazard Class: 6.1
UN Number: 3276
Packing Group: III
IMO
Shipping Name: NITRILES, TOXIC, N.O.S.
Hazard Class: 6.1
UN Number: 3276
Packing Group: III
RID/ADR
Shipping Name: NITRILES, TOXIC, N.O.S.
Hazard Class: 6.1
UN Number: 3276
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 20/21/22 Harmful by inhalation, in contact with
skin and if swallowed.
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
WGK (Water Danger/Protection)
CAS# 22446-12-4: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 22446-12-4 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 22446-12-4 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

合成制备方法

---

用途

---

反应信息

• 作为反应物：
  描述：

  4-甲氧基苯氧基乙腈 在 盐酸 、 sodium acetate 、 三乙胺 、 N,N'-二环己基碳二亚胺 、 zinc(II) chloride 作用下， 以 四氢呋喃 、 乙醚 、 乙醇 、 苯 为溶剂， 反应 31.0h， 生成 5-hydroxy-3-(4-methoxyphenoxy)-2-methyl-4-oxo-4H-chromen-7-yl N-(tert-butoxycarbonyl)-L-phenylalaninate
  参考文献：
  名称：

  5,7-dihydroxy-3-phenoxychromones: Synthesis and properties

  摘要：

  DOI：

  10.1007/bf02329590
• 作为产物：
  描述：

  4-甲氧基苯硼酸 、 溴乙腈 在 双氧水 、 sodium hydroxide 作用下， 以 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 以61%的产率得到4-甲氧基苯氧基乙腈
  参考文献：
  名称：

  含2-溴乙腈的基于芳基硼酸的芳氧基乙腈的合成

  摘要：

  使用环保型过氧化氢作为氧化剂，在无金属条件下，开发了一种新的有效方案，用于合成基于芳基硼酸和2-溴乙腈的芳氧基乙腈。该方法与芳基硼酸连接的敏感取代基兼容，并以中等至良好的产率获得所需产物。

  DOI：

  10.1016/j.tetlet.2020.152331

文献信息

• Copper-catalyzed transformation of alkyl nitriles to <i>N</i>-arylacetamide using diaryliodonium salts
  作者：Romain Sallio、Pierre-Adrien Payard、Paweł Pakulski、Iryna Diachenko、Indira Fabre、Sabine Berteina-Raboin、Cyril Colas、Ilaria Ciofini、Laurence Grimaud、Isabelle Gillaizeau

  DOI：10.1039/d1ra02305e

  日期：——

  This work reports a simple and efficient method for the copper-catalyzed redox-neutral transformation of alkyl nitriles using eco-friendly diaryliodonium salts and leading to N-arylacetamides. The method features high efficiency, broad substrate scope and good functional group tolerance.

  这项工作报告了一种简单有效的方法，用于使用环保的二芳基碘鎓盐对烷基腈进行铜催化的氧化还原中性转化并生成N-芳基乙酰胺。该方法效率高、底物范围广、官能团耐受性好。
• Substituted azabicyclic compounds
  申请人：Rhone-Poulenc Rorer Limited

  公开号：US06303600B1

  公开（公告）日：2001-10-16

  This invention is directed to certain physiologically active compounds of formula (I) wherein represents a bicyclic ring system, of about 10 to about 13 ring members, in which the ring is an azaheterocycle, and the ring represents an azaheteroaryl ring, or an optionally halo substituted benzene ring; and N-oxides thereof, and their prodrugs, and pharmaceutically acceptable salts and solvates of the compounds of formula (I) and N-oxides thereof, and their prodrugs. Such compounds inhibit the production or physiological effects of TNF and inhibit cyclic AMP phosphodiesterase. The invention is also directed to pharmaceutical compositions comprising compounds of formula (I), their pharmaceutical use and methods for their preparation.

  这项发明涉及公式（I）的某些生理活性化合物 其中 代表一个大约由10到13个环成员组成的双环环系统，其中该环 是一个氮杂环，并且该环 代表一个氮杂芳基环，或者一个可选地卤代苯环； 以及它们的N-氧化物，以及它们的前药，以及公式（I）的化合物及其N-氧化物的药用可接受的盐和溶剂合物，以及它们的前药。这些化合物抑制TNF的产生或生理效应，并抑制环磷酸腺苷磷酸二酯酶。该发明还涉及包括公式（I）的化合物的药物组合物，它们的药用以及其制备方法。
• HETEROCYCLIC COMPOUNDS
  申请人：Ishichi Yuji

  公开号：US20120088748A1

  公开（公告）日：2012-04-12

  Provided is a compound having a monoamine reuptake inhibitory activity, which is represented by the formula (I) wherein ring A is an optionally substituted 6-membered aromatic ring, ring B is the substituents on ring A are optionally bonded to form, together with ring A, an optionally substituted 9- or 10-membered aromatic fused ring, and other symbols are as defined in the specification, or a salt thereof.

  提供的是一种具有单胺再摄取抑制活性的化合物，其化学式表示为（I），其中环A是一个可选择取代的6元芳香环，环B是环A上的取代基可选择地与环A一起形成一个可选择取代的9或10元芳香融合环，其他符号如规范中定义的那样，或其盐。
• Combinatorial Synthesis and in Vitro Evaluation of a Biaryl Hydroxyketone Library as Antivirulence Agents against MRSA
  作者：Guanping Yu、David Kuo、Menachem Shoham、Rajesh Viswanathan

  DOI：10.1021/co400142t

  日期：2014.2.10

  crystallized. This strategy affords a range of biarylhydroxyketones in a single step. This is the first collective synthetic study documenting access to this class of compounds through a single synthetic operation. In vitro efficacy of compounds in this library was evaluated by a rabbit erythrocyte hemolysis assay. The most efficacious compound, 4f-12, inhibits hemolysis by 98.1 +/- 0.1% compared to

  抗生素抗性加上新抗生素的发展减少，因此有必要寻找新型抗菌剂。抗毒剂是常规抗生素的替代品。在这项工作中，我们报告了针对最广泛的细菌病原体耐甲氧西林金黄色葡萄球菌（MRSA）的小分子抗毒剂家族。结构-活性关系的研究导致了148位联芳基羟基酮库的简明合成方法的发展。酰化键形成过程提供间苯二酚（1）和芳氧基乙腈（2）作为合成子。进行路易斯酸活化的Friedel-Crafts酰化步骤，其中ZnCl2的腈官能度为2，然后亲核力为1，从而以优异的收率获得了联芳基羟基酮。大量产品结晶。此策略可在一个步骤中提供一系列联芳基羟基酮。这是第一个集体合成研究，它记录了通过单一合成操作对此类化合物的访问。该化合物在该文库中的体外功效通过兔红细胞溶血试验评估。与不存在该化合物的对照相比，最有效的化合物4f-12抑制溶血98.1 +/- 0.1％。
• [EN] CHROMENONE DERIVATIVES FOR TREATMENT OF CANCER<br/>[FR] DÉRIVÉS DE CHROMÉNONE POUR LE TRAITEMENT DU CANCER
  申请人：PROTEOLOGICS LTD

  公开号：WO2010134082A1

  公开（公告）日：2010-11-25

  4-Chromenone derivatives of the formula I herein that inhibit the ubiquitin-mediated degradation of p27, are useful for the treatment of cancer.

  本文中抑制泛素介导的p27降解的式I的4-香豆酮衍生物对于癌症的治疗是有用的。

表征谱图